Table 4. Ig-replacement therapy in primary and secondary antibody deficiency patients.

	PRIMARY	SECONDARY	p value
NUMBER OF SUBJECTS ON PROPHYLACTIC ANTIBIOTICS
Before starting Ig-replacement	47 (37.3%)	27 (69.2%)
After starting Ig-replacement	64 (50.8%)	23 (60.0%)
MEDIAN IgG DOSE, g/week (RANGE)	11.20 (3.2–32.0)	10.10 (3.2–30.0)	n.s. (0.4645)
(mean ± 95% C.I.)	(12.20±0.92)	(11.70±1.64)
MEDIAN IgG DOSE, g/kg (RANGE)	0.30 (0.10–1.30)	0.20 (0.10–2.00)	n.s. (0.1808)
(mean ± 95% C.I.)	(0.41±0.91)	(0.36±0.22)
MEDIAN IgG DOSE, g/kg/4-weeks (RANGE)	0.70 (0.35–2.03)	0.53 (0.35–1.03)	* 0.0110
(mean ± 95% C.I.)	(0.80±0.12)	(0.59±0.10)
MEDIAN TROUGH IgG, g/L (RANGE)	10.30 (5.46–18.93)	9.75 (6.35–13.70)	n.s. (0.1705)
(mean ± 95% C.I.)	(10.62±0.50)	(9.92±0.63)
MEDIAN NUMBER OF YEARS ON Ig-REPLACEMENT (RANGE)	3 (<1–28)	1 (<1–9)	* 0.0184
(mean ± 95% C.I.)	(3.77±0.87)	(2.54±0.74)
ROUTE OF ADMINISTRATION
IV	60 (47.6%)	13 (33.3%)
SC	66 (52.4%)	26 (66.6%)
PLACE OF ADMINISTRATION
Home	80 (63.5%)	25 (64.1%)
Barts Health	26 (20.6%)	9 (23.1%)
Other local hospital	20 (15.9%)	5 (12.8%)

Data were analysed with a two-tailed Mann-Whitney test; n.s., non-significant. IV indicates intravenous; and SC, sub-cutaneous.